Diasorin flies over the Ftse Mib on a day in which the stock market finally tries to rebound afterwards the nightmare sessions experienced in the last 10 days due to the coronavirus emergency.
The share of the company specializing in the immunodiagnostics and molecular diagnostics segments stands out above all the others, gaining 4,89% to 107,3 euros after having reached a maximum of 108,4 euros. To push the quotes is the news regarding the launch of an offering by Thermo Fischer Scientific on Qiagen, German company active in the supply of sampling and analysis technologies for molecular diagnostics, applied tests, academic and pharmaceutical research.
The offer is equal to 10,4 billion euros and values Qiagen at 39 euros per share, a figure that represents a 23% premium over the March 2 close. Not surprisingly, in Frankfurt the company's shares gained 18,2% to 37,6 euros, approaching the offer price of Thermo Fischer Scientific, a US company that develops biotechnological products.
Qiagen and Thermo Fisher, through a joint statement, have already made it known that their respective boards of directors and the executive committee of Qiagen have unanimously approved the proposal.
Future nuptials seem to please the market with all the stocks of the sector that travel in sharp rise. In Piazza Affari, the FTSE Italia Salute index rose by 3,7% to 205.127,68 points. Amplifon (+3,16%) and Recordati (+2,81%) are also on the back foot, while other stocks in the pharmaceutical sector are also in the spotlight: Roche (+3,1%) in Zurich, Siemens Healthineers (+ 2,76%) in Frankfurt, bioMerieux (+2,16%) in Paris.
“The news is positive for the sector as a whole because it increases the speculative appeal linked to consolidation hypotheses. Diasorin has a partnership with Qiagen for the commercialization of latent tuberculosis and Lyme disease,” Equita analysts explained.
DiaSorin and Qiagen on June 5 expanded their collaboration on QuantiFeron technology, with the development of a new test for the diagnosis of Lyme disease, aimed at providing a solution to the clinical needs of the market.
Diasorin would also have a doubly advantage, also because the agreement with Qiagen "is protected by some strong contractual clauses". “The only risk, underlines Equita, could be a lesser focus on the part of Qiagen, offset by a potential increase in the customer base that can be attacked”.
